These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 3224900)
1. [Pharmacological studies on MCNU: a new antitumor agent]. Sekido S; Hosono J; Hiratsuka K; Araki T; Iwasaki M Nihon Yakurigaku Zasshi; 1988 Aug; 92(2):69-96. PubMed ID: 3224900 [TBL] [Abstract][Full Text] [Related]
2. Antitumor activity and toxicity of methyl 6-[3-(2-chloroethyl)- 3-nitrosoureido]-6-deoxy-alpha-D-glucopyranoside in experimental animals. Fujimoto S; Tashiro T; Ogawa M Gan; 1984 Oct; 75(10):937-46. PubMed ID: 6510639 [TBL] [Abstract][Full Text] [Related]
3. Biologic activity of MCNU: a new antitumor agent. Sekido S; Ninomiya K; Iwasaki M Cancer Treat Rep; 1979 Jun; 63(6):961-70. PubMed ID: 466655 [TBL] [Abstract][Full Text] [Related]
4. General pharmacological properties of the new vasodilator flosequinan. Ikezono K; Fujita S; Umezato M; Hosoki E; Toba Y; Kusunoki A; Shintani S Arzneimittelforschung; 1992 Oct; 42(10):1200-11. PubMed ID: 1472141 [TBL] [Abstract][Full Text] [Related]
5. Neurotoxicity and pharmacokinetics of ventriculolumbar perfusion of methyl 6-[3-(2-chloroethyl)-3-nitrosoureido]-6-deoxy-alpha-D-glucopyranoside (MCNU) in dogs. Kochi M; Takaki S; Kuratsu J; Seto H; Kitamura I; Ushio Y J Neurooncol; 1994; 19(3):239-44. PubMed ID: 7807174 [TBL] [Abstract][Full Text] [Related]
6. [Action mechanism of methyl 6-[3-(2-chloroethyl)-3-nitrosoureido]-6-deoxy-alpha-D-glucopyranoside (MCNU) in leukemic cells]. Nakamura T; Hashimoto E; Sasada M; Tsutani H; Kagawa D; Ueda T; Uchida M; Domae N; Ando S; Uchino H Nihon Ketsueki Gakkai Zasshi; 1985 May; 48(3):734-41. PubMed ID: 3862320 [No Abstract] [Full Text] [Related]
7. General pharmacological properties of the main metabolite of flosequinan. Fujita S; Ikezono K; Umezato M; Hosoki E; Toba Y; Ishikawa M; Kusunoki A; Shintani S Arzneimittelforschung; 1992 Oct; 42(10):1212-22. PubMed ID: 1335257 [TBL] [Abstract][Full Text] [Related]
8. General pharmacological profile of the new cognition-enhancing agent nefiracetam. Kitano Y; Makino M; Usui C; Takasuna K; Kasai Y; Hirohashi M; Tamura K; Takayama S; Kojima H; Iizuka H Arzneimittelforschung; 1994 Feb; 44(2A):199-210. PubMed ID: 8018090 [TBL] [Abstract][Full Text] [Related]
9. General pharmacology of recombinant human basic fibroblast growth factor. Okumura M; Yajima M; Nishimura T; Ikeda H; Nishimori T Arzneimittelforschung; 1996 Jul; 46(7):727-39. PubMed ID: 8842346 [TBL] [Abstract][Full Text] [Related]
10. [Experimental studies on oral administration of nitrosourea anti-tumor agent, MCNU]. Sekido S; Ninomiya K; Araki T; Ueno M; Kinbara M Gan To Kagaku Ryoho; 1984 Jul; 11(7):1492-500. PubMed ID: 6234861 [TBL] [Abstract][Full Text] [Related]
11. [Pharmacological studies of guanabenz. Effects on the peripheral nervous and other organ systems]. Ohata K; Murata T; Sakamoto H; Kohno S; Hojo M; Yoshida Y; Nagasaka Y; Akimoto Y; Shimada A; Teramoto N; Tatsumi H Nihon Yakurigaku Zasshi; 1983 Jan; 81(1):59-78. PubMed ID: 6852682 [TBL] [Abstract][Full Text] [Related]
12. Beneficial treatment with methyl 6-[3-(2-chloroethyl)-3-nitrosoureido]-6-deoxy-alpha-D-glucopyranoside in a patient with primary myelofibrosis. Asano Y; Shimokawa M; Okabe H; Sanefuji H; Kato K Acta Haematol; 1991; 85(2):103-4. PubMed ID: 2024552 [TBL] [Abstract][Full Text] [Related]
13. [Phase II study on MCNU in patients with advanced or recurrent gastrointestinal cancer]. Niimoto M; Yoshinaka K; Hattori T; Kobayashi S; Hosoma S; Ogawa Y; Iwamori S; Nagata N; Yamagata S; Nishimawari K Gan To Kagaku Ryoho; 1985 Sep; 12(9):1813-9. PubMed ID: 4037810 [TBL] [Abstract][Full Text] [Related]
14. [Phase II study of methyl 6-[3-(2-chloroethyl)-3-nitrosoureido]-6-deoxy-alpha-D-glucopyranoside (MCNU)]. Tanaka I; Kobayashi T; Shirakawa S; Ikeda Y; Kobayashi M; Yamagata K; Ohta K; Ohno R; Yamada H; Yamada K Gan To Kagaku Ryoho; 1985 Mar; 12(3 Pt 1):493-8. PubMed ID: 3859248 [TBL] [Abstract][Full Text] [Related]
15. [Antitumor activity of a new nitrosourea, MCNU, on a cellular morphological basis evaluated by a new in vitro antitumor sensitivity assay]. Oguro M; Yanagawa T; Takenaga K Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 1):2550-6. PubMed ID: 6594974 [TBL] [Abstract][Full Text] [Related]
16. Effect of the nitrosourea anti-tumor chemotherapeutical agent MCNU on five human myeloma cell lines. Otsuki T; Sakaguchi H; Yamada O; Yawata Y; Ueki A Oncol Rep; 1998; 5(4):827-32. PubMed ID: 9625826 [TBL] [Abstract][Full Text] [Related]
17. [General pharmacology of T-3262, a new pyridonecarboxylic acid]. Hirai S; Hiraiwa T; Arai H; Ono S; Tanaka K; Hashiba K; Nakada Y; Goden K; Tanada K; Maekawa M Jpn J Antibiot; 1989 Apr; 42(4):831-53. PubMed ID: 2769937 [TBL] [Abstract][Full Text] [Related]
18. General pharmacology of the new antimuscarinic compound vamicamide. Yamamoto T; Honbo T; Tokoro K; Kojimoto Y; Kodama R; Ohtsuka M; Shimomura K Arzneimittelforschung; 1995 Dec; 45(12):1274-84. PubMed ID: 8595084 [TBL] [Abstract][Full Text] [Related]
19. General pharmacological profiles of the new beta-adrenoceptor antagonist carvedilol. Hirohashi M; Takasuna K; Tamura K; Yamaguchi K; Maekawa K; Yamada S; Iwasaki S; Yoshida M; Nomura M; Taguchi K Arzneimittelforschung; 1990 Jul; 40(7):735-46. PubMed ID: 1977393 [TBL] [Abstract][Full Text] [Related]
20. [Pharmacological studies of 4-ethoxy-2-methyl-5-morpholino-3(2H)-pyridazinone (M73101). (3). General pharmacological actions (author's transl)]. Sato M; Ishizuka Y; Tanizawa H; Fukuda T; Yuizono T Nihon Yakurigaku Zasshi; 1979 Apr; 75(3):291-307. PubMed ID: 317064 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]